FDA Grants Accelerated Approval for Voceryq, First Plasmid DNA-Based Immunotherapy

The FDA's accelerated approval of Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) on October 30, 2026, opens a manufacturing and regulatory frontier that plant heads and QA directors cannot afford to treat as a distant concern. As the first plasmid DNA-based immunotherapy approved in the U.S., Voceryq sets a precedent that will shape CBER inspection readiness expectations for every facility pursuing DNA-based biologics.

Voceryq is indicated for adults with recurrent respiratory papillomatosis (RRP), a rare, chronic HPV-driven condition requiring repeated surgical removal of airway papillomas. The therapy delivers two recombinant plasmids, one encoding HPV type 6 and 11 proteins, the other encoding IL-12, via intramuscular injection combined with electroporation using the CELLECTRA 5PSP Device. That device-drug combination introduces a dual regulatory burden: biologics manufacturing controls under 21 CFR Part 610 alongside device quality system requirements, a pairing that will demand close coordination between QA and regulatory affairs teams at any contract or captive manufacturing site.

Approval rested on an open-label multicenter trial in 32 adults. Of 26 patients with at least three baseline surgeries in the prior 12 months, seven (27%) required no surgical intervention in the first year post-treatment. The FDA accepted reduction in surgical frequency as an intermediate clinical endpoint reasonably likely to predict clinical benefit, the standard accelerated approval basis. The manufacturer is obligated to conduct confirmatory trials to verify and describe clinical benefit, meaning the post-approval regulatory workload is substantial and ongoing.

For manufacturing and quality operations, the approval signals that plasmid DNA production at commercial scale is now a live GMP concern, not a pipeline abstraction. Plasmid manufacturing introduces distinct process validation challenges: supercoiled isoform consistency, endotoxin control, residual host-cell DNA limits, and cold-chain integrity across a product that is biologically active at the nucleic acid level. Facilities scaling plasmid production will need to demonstrate comparability across batches under ICH Q5E and align their process validation packages with the expectations CBER has now implicitly codified through this approval. The contract manufacturing ecosystem for DNA-based biologics should expect heightened scrutiny as sponsors seek CDMOs with demonstrated plasmid GMP capability.

Reported adverse reactions included injection site reactions, headache, fatigue, hypertension, and nausea, a safety profile that will inform labeling and handling SOPs at clinical and commercial administration sites.

The confirmatory trial requirement means Voceryq's regulatory file will remain active and subject to CBER review for years, making post-approval change management and annual product review discipline critical checkpoints for the sponsor's quality system.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov press announcement, October 30, 2026.